

Edgar Filing: ELAN CORP PLC - Form 6-K

ELAN CORP PLC
Form 6-K
April 13, 2005

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the month of April, 2005

Commission File Number 001-13896

Elan Corporation, plc
(Translation of registrant's name into English)

Treasury Building, Lower Grand Street, Dublin 2, Ireland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F /X/ Form 40-F / /

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):

Yes / / No /X/

Note: Regulation S-T Rule 101(b) (1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):

Yes / / No /X/

-2-

Note: Regulation S-T Rule 101(b) (7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally

Edgar Filing: ELAN CORP PLC - Form 6-K

organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes / / No /X/

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

This Report of Foreign Issuer on Form 6-K is incorporated by reference into the Post-Effective Amendments on Forms F-3 and S-8 to Form F-4 Registration Statement of Elan Corporation, plc (Registration No. 333-12756), the Registration Statement on Form F-3 of Elan Corporation, plc and Athena Neuroscience Finance, LLC (Registration No. 333-13130), and the Registration Statements on Form S-8 of Elan Corporation, plc (Registration Nos. 333-13996, 333-12344, 333-11940, 333-09644, 333-09284, 333-09048, 333-08384, 333-07361, 333-07136, 333-14240, 33-27506 and 333-100252).

EXHIBIT LIST

Exhibit	Description
99.1	Press release dated April 12, 2005 titled: TYSABRI(R) two-year monotherapy data support positive one-year efficacy findings and show significant reduction in risk of disability progression. Data presented at American Academy of Neurology meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

Edgar Filing: ELAN CORP PLC - Form 6-K

undersigned, thereunto duly authorized.

ELAN CORPORATION, plc

By: /s/ William F. Daniel

William F. Daniel
Company Secretary

Date: April 12, 2005

Exhibit 99.1

For More Information Contact:

MEDIA CONTACTS:

Biogen Idec
Amy Brockelman
Ph: 617 914 6524

Elan
Anita Kawatra or
Brian McGlynn
Ph: 212 407 5740
800 252 3526

INVESTOR CONTACTS:

Biogen Idec
Elizabeth Woo
Ph: 617 679 2812

Elan
Emer Reynolds
Ph: 353 1 709 4000
800 252 3526

TYSABRI (R) TWO-YEAR MONOTHERAPY DATA SUPPORT POSITIVE ONE-YEAR EFFICACY
FINDINGS AND SHOW SIGNIFICANT REDUCTION IN RISK OF DISABILITY
PROGRESSION

Data Presented at American Academy of Neurology Meeting

Cambridge, MA and Dublin, Ireland - April 12, 2005 -Two-year data from the AFFIRM Phase III monotherapy trial presented today for the first time, showed that treatment with TYSBARI(R) (natalizumab) led to a significant reduction in disability progression, the rate of clinical relapses and brain lesions in patients with relapsing forms of multiple sclerosis (MS). These data were presented at the 57th annual American Academy of Neurology (AAN) meeting in Miami Beach, FL.

AFFIRM met all primary and secondary endpoints, including disability progression and relapse rate. TYSABRI treatment was also associated with a low level of immunogenicity.

TYSABRI treatment led to a 42 percent (p=0.0002) reduction in the risk of disability progression compared to placebo. TYSABRI also reduced the rate of clinical relapses by 67 percent (p